Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

Pharmacokinetic Assessment

Pharmacokinetic Assessment

Alfa Cytology has broad and deep expertise in drug metabolism and pharmacokinetic (DMPK) research and provides our customers with tailored, innovative, and integrated drug discovery and therapy development solutions. Whether in drug screening, PK analysis, or all therapy development stages, we can help customers improve the efficiency of research and development and the speed of translation of results through professional knowledge and advanced methods.

Introduction to Pharmacokinetics

PK mainly studies the human body's interactions with drugs, focusing on understanding the absorption, distribution, metabolism, and elimination processes (ADME) of drugs in the body. The complex interplay of drug and organism dynamics helps determine the concentration and duration of action of drugs in different tissues, laying the foundation for designing optimal dose regimens and predicting drug behavior in different populations.

In terms of PK processes, drugs undergo four stages, absorption, distribution, metabolism, and excretion.Fig. 1 Pharmacokinetics absorption, distribution, metabolism, and excretion (ADME) of personalized drugs. (Alghamdi, M.A., et al., 2022)

The drug enters the body from the site of administration. Subsequent systemic distribution involves the drug reaching the target tissue or organ through the bloodstream. Once the drug reaches its target, metabolism occurs, with enzymes breaking the drug down into metabolites that can be eliminated from the body. Finally, elimination involves the removal of the drug and its metabolites through processes such as renal excretion or hepatic clearance.

Our Services

Alfa Cytology's PK division has expertise and extensive experience in both integrated drug discovery and standalone PK services. PK facilities include state-of-the-art in vitro ADME and tissue culture laboratories, animal facilities for in vivo PK studies on rats, mice, and dogs, and bioanalytical laboratories equipped with high-end LC-MS/MS instruments for Cmax and T1/2 testing . We design and analyze customized solutions according to customer or project requirements.

Comprehending the in vitro pharmacokinetic properties is crucial for drug development. Alfa Cytology offers a variety of in vitro PK services.

  • High-throughput ADME screening
  • In vitro binding
  • In vitro metabolism
  • In vitro permeability

Alfa Cytology provides in vivo pharmacokinetics (PK) services to support drug development research.

  • PK biomarker analysis
  • Bioanalytical package
  • Mass balance
  • Administration routes
  • Metabolite profiling and identification

Alfa Cytology provides high-quality drug-drug interaction services.

  • Cytochrome P450 induction assay
  • Cytochrome P450 inhibition assay
  • UGT induction
  • UGT inhibition
  • CYP and UGT reaction phenotyping assay

Alfa Cytology provides professional testing services to help customers determine the bioavailability and bioequivalence of drugs.

  • Drug dosing routes
  • Drug dosage
  • Endpoints
  • Animal species

Why Choose Us?

Customized solution Highly-experienced expert team Variety of preclinical models Quick turnaround time Worldwide service

Alfa Cytology has expertise in designing and performing PK assessment studies and can tailor experimental protocols to your project needs. We not only focus on the accuracy and cutting-edge of research but also strive to effectively reduce the turnaround time of drug development by optimizing processes and technical means. We will be your best partner with high quality and fast turnaround service. Please contact us for more information about our services.

Reference

  1. Alghamdi, M.A.; et al. The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 2022, 12, 673. https://doi.org/10.3390/jpm12050673
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.